Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
WXSH0011
i
Other names:
WXSH0011
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(5)
News
Trials
Company:
WuXi AppTec
Drug class:
FGFR inhibitor, c-MET inhibitor
Related drugs:
‹
infigratinib (53)
futibatinib (52)
pemigatinib (41)
BAY 1163877 (23)
Debio 1347 (17)
ARQ 087 (12)
TKI258 (9)
CPL304110 (4)
E 3810 (4)
KIN-3248 (3)
AZ8010 (2)
HX301 (2)
tasurgratinib (2)
MPT0L145 (1)
PRN1371 (1)
BAY 1179470 (0)
EOC317 (0)
TAR-210 (0)
PI-88 (0)
TSU-68 (0)
SYHA1817 (0)
SSR 128129 (0)
SYHA1815 (0)
XL228 (0)
savolitinib (29)
amivantamab-vmjw (25)
tepotinib (24)
capmatinib (23)
TPX-0022 (8)
CKD-702 (6)
GB263T (5)
gumarontinib (5)
ARQ 197 (5)
REGN5093 (4)
MGCD265 (4)
AMG 102 (4)
envonalkib (3)
MCLA-129 (3)
ABN401 (3)
BPI-9016 (2)
HS-10241 (2)
AV-299 (2)
GSK1363089 (2)
HQP8361 (2)
S95027 (2)
APL-101 (2)
DO-1 (1)
LY2875358 (1)
GST-HG161 (1)
E7050 (1)
JNJ-38877605 (1)
KRC-108 (1)
RG3638 (1)
SGX523 (1)
SU11274 (1)
AL2846 (0)
AMG 208 (0)
AMG 337 (0)
ARGX-111 (0)
ASKC202 (0)
ASLAN002 (0)
EMB-01 (0)
DO-2 (0)
EMD 1204831 (0)
HLX55 (0)
BMS-794833 (0)
MRX34 (0)
PF-04217903 (0)
PHA665752 (0)
PM1080 (0)
RXDX-106 (0)
amivantamab and hyaluronidase-lpuj (0)
S-49076 (0)
SAIT301 (0)
SAR 125844 (0)
SPH 3348 (0)
TAVO412 (0)
h224G11 (0)
infigratinib (53)
futibatinib (52)
pemigatinib (41)
BAY 1163877 (23)
Debio 1347 (17)
ARQ 087 (12)
TKI258 (9)
CPL304110 (4)
E 3810 (4)
KIN-3248 (3)
AZ8010 (2)
HX301 (2)
tasurgratinib (2)
MPT0L145 (1)
PRN1371 (1)
BAY 1179470 (0)
EOC317 (0)
TAR-210 (0)
PI-88 (0)
TSU-68 (0)
SYHA1817 (0)
SSR 128129 (0)
SYHA1815 (0)
XL228 (0)
savolitinib (29)
amivantamab-vmjw (25)
tepotinib (24)
capmatinib (23)
TPX-0022 (8)
CKD-702 (6)
GB263T (5)
gumarontinib (5)
ARQ 197 (5)
REGN5093 (4)
MGCD265 (4)
AMG 102 (4)
envonalkib (3)
MCLA-129 (3)
ABN401 (3)
BPI-9016 (2)
HS-10241 (2)
AV-299 (2)
GSK1363089 (2)
HQP8361 (2)
S95027 (2)
APL-101 (2)
DO-1 (1)
LY2875358 (1)
GST-HG161 (1)
E7050 (1)
JNJ-38877605 (1)
KRC-108 (1)
RG3638 (1)
SGX523 (1)
SU11274 (1)
AL2846 (0)
AMG 208 (0)
AMG 337 (0)
ARGX-111 (0)
ASKC202 (0)
ASLAN002 (0)
EMB-01 (0)
DO-2 (0)
EMD 1204831 (0)
HLX55 (0)
BMS-794833 (0)
MRX34 (0)
PF-04217903 (0)
PHA665752 (0)
PM1080 (0)
RXDX-106 (0)
amivantamab and hyaluronidase-lpuj (0)
S-49076 (0)
SAIT301 (0)
SAR 125844 (0)
SPH 3348 (0)
TAVO412 (0)
h224G11 (0)
›
Associations
(5)
News
Trials
VERI cancer hierarchy
Reset Filters
FGFR overexpression + MET overexpression
Hepatocellular Cancer
FGFR overexpression + MET overexpression
Hepatocellular Cancer
WXSH0011
Sensitive: D – Preclinical
WXSH0011
Sensitive
:
D
WXSH0011
Sensitive: D – Preclinical
WXSH0011
Sensitive
:
D
MET overexpression
Hepatocellular Cancer
MET overexpression
Hepatocellular Cancer
WXSH0011
Sensitive: D – Preclinical
WXSH0011
Sensitive
:
D
WXSH0011
Sensitive: D – Preclinical
WXSH0011
Sensitive
:
D
FGFR overexpression
Hepatocellular Cancer
FGFR overexpression
Hepatocellular Cancer
WXSH0011
Sensitive: D – Preclinical
WXSH0011
Sensitive
:
D
WXSH0011
Sensitive: D – Preclinical
WXSH0011
Sensitive
:
D
FGFR overexpression
Gastric Cancer
FGFR overexpression
Gastric Cancer
WXSH0011
Sensitive: D – Preclinical
WXSH0011
Sensitive
:
D
WXSH0011
Sensitive: D – Preclinical
WXSH0011
Sensitive
:
D
MET overexpression
Gastric Cancer
MET overexpression
Gastric Cancer
WXSH0011
Sensitive: D – Preclinical
WXSH0011
Sensitive
:
D
WXSH0011
Sensitive: D – Preclinical
WXSH0011
Sensitive
:
D
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.